Clinical characteristics and transfusion strategies of delayed serological transfusion reactions caused by platelet transfusion in tumor patients
10.13303/j.cjbt.issn.1004-549x.2024.05.001
- VernacularTitle:肿瘤患者血小板输注致迟发性血清学输血反应的临床特征及输血策略
- Author:
Min LIU
1
;
Tao PENG
1
;
Jingjing YU
1
;
Ruijuan ZHAO
1
;
Weiwei FANG
1
;
Juan CAI
1
;
Simeng CHEN
1
;
Xiying LI
1
Author Information
1. Department of Blood Transfusion, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China
- Publication Type:Journal Article
- Keywords:
tumor patients;
platelet transfusion;
delayed serological transfusion reactions(DSTR)
- From:
Chinese Journal of Blood Transfusion
2024;37(5):491-494
- CountryChina
- Language:Chinese
-
Abstract:
【Objective】 To analyze the clinical manifestations of delayed serological transfusion reactions (DSTR) after platelet transfusion in tumor patients, and to explore the transfusion strategy. 【Methods】 Clinical data and laboratory test results of patients with positive antibody screening were analyzed after platelet transfusion in our hospital from January 1, 2015 to June 30, 2023, and the incidence rate, clinical characteristics and transfusion strategy of patients with DSTR were analyzed. 【Results】 A total of 2 553 patients with 6 057 platelet transfusions were reviewed. Eight patients developed DSTR and received a total of 21 therapeutic amounts of platelets, and 5 patients were subsequently transfused with red blood cells. Rh system antibodies were detected in 7 cases (4 anti-E, 1 anti-c/E, 1 anti-C and 1 anti-c) and Kell system antibodies in 1 case. 【Conclusion】 Tumor patients may also develop DSTR after platelet transfusion. It is necessary to pay close attention to the antibody situation and perform matched transfusion when transfusing blood again.
